En vivo
Novo NordiskA proposal seeks to remove Novo and Lilly drugs from key list in the US – will provide better protection against copies - medwatch.comFierceBiotechAmgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 dataAmgenAmgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce BiotechSamsung Biologics(LEAD) Samsung Biologics union launches 1st general strike over pay dispute - Yonhap News AgencySamsung BiologicsSamsung Biologics, Lilly to Launch Biotech Hub Supporting Venture Ecosystem - Seoul Economic DailyBioPharma DiveTwo biotechs raise a combined $556M in latest spurt of IPOsMerck & Co.Spotlight On: Merck & Co. maintains BD appetite ahead of $70B sales goal - FirstWord PharmaSiemens HealthineersSiemens Healthineers Faces a Reckoning: Diagnostics Sale, Spin-Off Delays, and a Stock at Rock Botto - AD HOC NEWSSamsung BiologicsSamsung Biologics union launches 1st general strike over pay dispute - The Korea TimeseLifeAdapting clinical chemistry plasma as a source for liquid biopsiesThermo FisherHow Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo FinanceNovo NordiskNovo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO - Bloomberg.com
Bio-Rad 30 abr 2026

Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus

Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus

Original
Contenido no disponible. Consulta la fuente original.